NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price.
Lynparza – a poly ADP ribose polymerase (PARP) inhibitor – has been deemed by NICE as “not cost-effective at its current price” as a treatment option for BRCA-positive prostate cancer that has spread to other parts of the body and relapsed following prior hormonal therapy.
In 2021, NICE rejected Lynparza for this indication and then again earlier this year, in a decision that was underpinned by issues around cost, since the regulator had stated the clinical evidence supported the overall efficacy of the drug in relapsed, BRCA-positive prostate cancer…
